Tisagenlecleucel

Global CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis & Forecasts, 2017-2020 & 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
星期二, 九月 21, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Therapy, White blood cell, Ministry, Multiple myeloma, Novartis, List of health departments and ministries, FDA, Juno Therapeutics, Cancer, Patient, DLBCL, European Medicines Agency, Bristol Myers Squibb, Lymphoma, Acquisition, Diffuse large B-cell lymphoma, Growth, Awareness, MM, MHLW, EMA, Industry, Tisagenlecleucel, Vaccine, Pharmaceutical industry

The "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients' immune cells to fight cancer.
  • This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market.
  • Majority of the companies have already started investing in them to gain a better market share in this industry.

Cellular Immunotherapy Global Markets Report 2021: Focus on TIL Therapy, Engineered TCR Therapy, Chimeric Antigen Receptor, T Cell Therapy & Natural Killer (NK) Cell Therapy - ResearchAndMarkets.com

Retrieved on: 
星期四, 八月 12, 2021
Health, Biotechnology, Research, Cell, Patient, Liver cancer, Bristol Myers Squibb, Breast cancer, Gilead Sciences, Immune system, Lung cancer, COVID-19, JW, AstraZeneca, Pfizer, Growth, Cancer, TCR, Prostate cancer, Roche, CAR, Clinical trial, Ovarian cancer, Non-Hodgkin lymphoma, Acute leukemia, Tisagenlecleucel, Novartis, Kite Pharma, Renal cell carcinoma, TIL, Skin cancer, Brain, Creagen Dow, Technology, NK, Pharmaceutical industry, Mobile phone, Medical imaging

The "Cellular Immunotherapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cellular Immunotherapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The cellular immunotherapy market consists of revenues generated by the companies engaged in developing, manufacturing, and sales of cellular immunotherapy drugs.
  • The cellular immunotherapy market covered in this report is segmented by therapy into tumor-infiltrating lymphocyte (TIL) therapy; engineered T cell receptor (TCR) therapy; chimeric antigen receptor (CAR) T cell therapy; natural killer (NK) cell therapy.
  • Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period.

Cell Therapy Technologies Global Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
星期二, 八月 10, 2021
Health, Science, Stem Cells, Pharmaceutical, Research, Aviation, Industry, Tisagenlecleucel, Pressure, Software, Renewable energy, CAGR, Danaher Corporation, GE, CVD, Cancer, Disorder, Cardiovascular disease, General Electric, COVID-19, Research, CAR, Cell, General Electric Company, Population, Acquisition, Investment, Government, Growth, GDP, Pharmaceutical industry

The "Cell Therapy Technologies Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Therapy Technologies Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The cell therapy technologies market consists of sales of cell therapy technologies that are medicinal solutions used for developing and improving cell therapy, such as cell processing, cell banking, and point-of-care technologies.
  • Increasing investments by the government in cell-based research contributed to the growth of the global cell therapy technologies market.
  • Strategic collaborations and partnerships between the industry players are gaining popularity in the cell therapy technologies market.

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
星期二, 六月 22, 2021
Non-Hodgkin lymphoma, Lymphoma, Clinical medicine, Medical specialties, Medicine, Orphan drugs, Antineoplastic drugs, Diffuse large B-cell lymphoma, Loncastuximab tesirine, Tisagenlecleucel

OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation.

Key Points: 
  • OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation.
  • The initial results from the completed Phase I study (n=16 treated with Betalutin) show that Betalutin was well tolerated, with a good safety profile consistent with all previous studies with Betalutin.
  • Peter Braun, Nordic Nanovector CEO, commented: "We continue to be very encouraged by the overall safety profile that Betalutin exhibits in even the most fragile and highly pre-treated NHL patients.
  • Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse large B cell lymphoma (2014) South Asian J.

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
星期二, 六月 22, 2021
Non-Hodgkin lymphoma, Lymphoma, Clinical medicine, Medical specialties, Medicine, Orphan drugs, Antineoplastic drugs, Diffuse large B-cell lymphoma, Loncastuximab tesirine, Tisagenlecleucel

OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation.

Key Points: 
  • OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation.
  • The initial results from the completed Phase I study (n=16 treated with Betalutin) show that Betalutin was well tolerated, with a good safety profile consistent with all previous studies with Betalutin.
  • Peter Braun, Nordic Nanovector CEO, commented: "We continue to be very encouraged by the overall safety profile that Betalutin exhibits in even the most fragile and highly pre-treated NHL patients.
  • Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse large B cell lymphoma (2014) South Asian J.

Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation

Retrieved on: 
星期五, 六月 4, 2021
Research, FDA, Hospitals, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical medicine, Medicine, Orphan drugs, Health sciences, Breakthrough therapy, Gene therapy, Gilead Sciences, Brexucabtagene autoleucel, Inotuzumab ozogamicin, Tisagenlecleucel

In the pivotal Phase 2 portion of the trial, 71 patients with relapsed or refractory disease were enrolled.

Key Points: 
  • In the pivotal Phase 2 portion of the trial, 71 patients with relapsed or refractory disease were enrolled.
  • If approved, Tecartus would become the first and only CAR T-cell therapy approved for adults (18 years old) with relapsed or refractory ALL.
  • In 2016, Tecartus received Breakthrough Therapy Designation in recognition of the unmet medical need in adult patients with relapsed or refractory B-cell precursor ALL.
  • Tecartus has not been approved by any regulatory agency for the treatment of adult patients with relapsed or refractory ALL.

Global CAR-T Cell Therapy Market Report 2021 - Size, Forecasts, Trials & Trends - ResearchAndMarkets.com

Retrieved on: 
星期三, 六月 2, 2021
Biotechnology, Pharmaceutical, Health, Clinical medicine, Medicine, Health sciences, Gene therapy, Gilead Sciences, Breakthrough therapy, Orphan drugs, Cancer treatments, Chimeric antigen receptor T cell, Kite Pharma, Tisagenlecleucel, Brexucabtagene autoleucel

Presently, this hematological arena is highly competitive and is being targeted by numerous CAR-T cell therapy competitors.

Key Points: 
  • Presently, this hematological arena is highly competitive and is being targeted by numerous CAR-T cell therapy competitors.
  • CAR-T cell products targeted against solid tumors will undoubtedly offer a larger market potential.
  • Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma produced Yescarta, a CAR-T therapy designed for patients with lymphoma.
  • In July 2020, the U.S. FDA approved the third CAR-T cell therapy, approving Kite Pharma's brexucabtagene autoleucel, sold as Tecartus.

Prime Therapeutics' study shows total cost of care for CAR-T plus post-treatment events can exceed $1 million

Retrieved on: 
星期一, 四月 12, 2021
Clinical medicine, Medicine, Gene therapy, Health sciences, Healthcare reform in the United States, Breakthrough therapy, Orphan drugs, Federal assistance in the United States, Chimeric antigen receptor T cell, Medicare, Medicaid, Tisagenlecleucel

Although CAR-T product to treat B-cell lymphoma wholesale acquisition cost is $373,000, real-world data from a recent Prime study showed the total cost for members receiving CAR-T therapy (Kymriah or Yescarta) averaged more than $700,000, and in some cases exceeded $1 million.

Key Points: 
  • Although CAR-T product to treat B-cell lymphoma wholesale acquisition cost is $373,000, real-world data from a recent Prime study showed the total cost for members receiving CAR-T therapy (Kymriah or Yescarta) averaged more than $700,000, and in some cases exceeded $1 million.
  • The total cost of care from members during the initial CAR-T therapy period ranged from $350,000 to more than $2 million.
  • The cost for CAR-T treatment medication alone was $527,00 on average roughly three-fourths (74%) of the total cost during the initial treatment period.
  • Prime provides total drug management solutions for health plans, employers, and government programs including Medicare and Medicaid.

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Retrieved on: 
星期四, 四月 1, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical trials, Clinical medicine, Medicine, Health sciences, Breakthrough therapy, Gene therapy, Orphan drugs, Gilead Sciences, Cancer treatments, Brexucabtagene autoleucel, Tisagenlecleucel, Kite Pharma

Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
  • In 2017, Tecartus was granted Breakthrough Therapy Designation by the FDA for relapsed or refractory adult B-cell precursor ALL.
  • Tecartus has not been approved by any regulatory agency for the treatment of adult patients with relapsed or refractory ALL.
  • In ZUMA-2, CRS occurred in 91% (75/82) of patients receiving Tecartus, including Grade 3 CRS in 18% of patients.

T-cell Therapy Market Size Worth $20.3 Billion By 2028 | CAGR: 20.2%: Grand View Research, Inc.

Retrieved on: 
星期四, 二月 18, 2021
Health sciences, Life sciences, Branches of biology, Gene therapy, Biotechnology, Actuarial science, Compound annual growth rate, Mathematical finance, Therapy, Tisagenlecleucel, Cell therapy, Modality

SAN FRANCISCO, Feb. 18, 2021 /PRNewswire/ -- The global T-cell therapy market size is expected to reach USD 20.3 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 18, 2021 /PRNewswire/ -- The global T-cell therapy market size is expected to reach USD 20.3 billion by 2028, according to a new report by Grand View Research, Inc.
  • The market is expected to expand at a CAGR of 20.2% from 2021 to 2028.
  • The milestone approvals of Kymriah and Yescarta along with the recent approval of Tecartus have bolstered the exponential revenue growth in the market.
  • Grand View Research has segmented the T-cell therapy market on the basis of modality, therapy type, indications, and regions:
    T-cell Therapy Modality Outlook (Revenue, USD Million, 2017 - 2028)
    T-cell Therapy Type Outlook (Revenue, USD Million, 2017 - 2028)